Abstract 10724: Effect of LDL Cholesterol Level on Lipoprotein(a)-Associated Cardiovascular Risk in Stable Coronary Heart Disease
Abstract
Background: Elevated lipoprotein(a) [Lp(a)] is an independent causal cardiovascular risk factor affecting approximately 20% of the population. Whether this enhanced risk persists in individuals on treatment with low LDL-C levels remains a subject of controversy. We hypothesized that achieving LDL <70 mg/dL would attenuate risk in patients with elevated Lp(a) and stable CAD. Methods: We identified 4,806 patients with measured Lp(a) enrolled in the Emory Cardiovascular Biobank, a prospective cohort of adults undergoing clinically indicated cardiac catheterization for suspected CAD. Patients were divided into four mutually exclusive groups based on Lp(a) (<50 vs. ≥50 mg/dL) and LDL-C (<70 vs. ≥70 mg/dL) and followed for incident MACE (CV death and non-fatal MI). Fine-Gray hazard models were used to compare event rates with non-cardiovascular death as a competing risk after adjusting for age, sex, BMI, DM, HTN, eGFR, total cholesterol (TC), HDL-C, hsCRP, smoking history, and statin use. Results: Median age of the cohort was 63 ± 12 years, 64.7% were male, and 76.7% were White. In the LDL-C ≥70 mg/dL stratum, patients with elevated Lp(a) were more frequently female and Black individuals and had higher TC, hsCRP, and statin use compared to those with lower Lp(a). Within the LDL-C <70 mg/dL stratum, baseline characteristics were similar between Lp(a) groups, except for more frequent statin use among patients with elevated Lp(a). Among patients with LDL-C ≥70mg/dL (n= 3546), elevated Lp(a) was associated with significantly higher 5-year cumulative MACE incidence before (Gray's p=0.0006; Figure 1 ) and after adjustment (sHR 1.29, 95% CI 1.09-1.52, p=0.004) compared to those with lower Lp(a). In contrast, among patients with LDL <70 mg/dL (n=1260), elevated Lp(a) was not significantly associated with higher MACE incidence before ( Figure 2 ) or after adjustment (sHR 0.98, 95% CI 0.70-1.36, p=0.88). Conclusions: Among patients with stable CAD, elevated Lp(a) was independently associated with MACE in those with LDL-C ≥70 mg/dL but not in those with LDL-C <70 mg/dL. These findings suggest that elevated Lp(a) may confer little additional cardiovascular risk among CAD patients with on-treatment LDL-C <70 mg/dL. Further prospective evaluation is needed.